These have recently been revised. Co-trimoxazole is now licensed for the treatment of urinary tract infections and acute exacerbations of chronic bronchitis but only where there is bacterial evidence of sensitivity to co-trimoxazole and good reason to prefer the combination to a single antibiotic. The circumstances where 'good reason' applies where not defined by the licensing authority.
In children, co-trimoxazole is licensed for the treatment of acute otitis media in children where there is good reason to prefer co-trimoxazole to a single antibiotic.
Co-trimoxazole is the first line treatment for pneumocystis carinii. The drug is also licensed for the treatment and prevention of toxoplasmosis and the treatment of nocardiasis.
Annotations allow you to add information to this page that would be handy to have on hand during a consultation. E.g. a website or number. This information will always show when you visit this page.